531 related articles for article (PubMed ID: 30861111)
1. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
[TBL] [Abstract][Full Text] [Related]
2. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
3. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
[TBL] [Abstract][Full Text] [Related]
4. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
Ganguly BB; Banerjee D; Agarwal MB
Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
[TBL] [Abstract][Full Text] [Related]
5. Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure.
Dorsheimer L; Assmus B; Rasper T; Ortmann CA; Ecke A; Abou-El-Ardat K; Schmid T; Brüne B; Wagner S; Serve H; Hoffmann J; Seeger F; Dimmeler S; Zeiher AM; Rieger MA
JAMA Cardiol; 2019 Jan; 4(1):25-33. PubMed ID: 30566180
[TBL] [Abstract][Full Text] [Related]
6. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
Gillis NK; Ball M; Zhang Q; Ma Z; Zhao Y; Yoder SJ; Balasis ME; Mesa TE; Sallman DA; Lancet JE; Komrokji RS; List AF; McLeod HL; Alsina M; Baz R; Shain KH; Rollison DE; Padron E
Lancet Oncol; 2017 Jan; 18(1):112-121. PubMed ID: 27927582
[TBL] [Abstract][Full Text] [Related]
7. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
[TBL] [Abstract][Full Text] [Related]
8. [Clonal hematopoiesis in aplastic anemia and paroxysmal nocturnal hemoglobinuria].
Makishima H
Rinsho Ketsueki; 2022; 63(9):1042-1045. PubMed ID: 36198527
[TBL] [Abstract][Full Text] [Related]
9. Consequences of mutant TET2 on clonality and subclonal hierarchy.
Hirsch CM; Nazha A; Kneen K; Abazeed ME; Meggendorfer M; Przychodzen BP; Nadarajah N; Adema V; Nagata Y; Goyal A; Awada H; Asad MF; Visconte V; Guan Y; Sekeres MA; Olinski R; Jha BK; LaFramboise T; Radivoyevitch T; Haferlach T; Maciejewski JP
Leukemia; 2018 Aug; 32(8):1751-1761. PubMed ID: 29795413
[TBL] [Abstract][Full Text] [Related]
10. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.
Tefferi A; Lasho TL; Patnaik MM; Saeed L; Mudireddy M; Idossa D; Finke C; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2017 Dec; 92(12):1311-1317. PubMed ID: 28875545
[TBL] [Abstract][Full Text] [Related]
11. Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays.
Coombs CC; Gillis NK; Tan X; Berg JS; Ball M; Balasis ME; Montgomery ND; Bolton KL; Parker JS; Mesa TE; Yoder SJ; Hayward MC; Patel NM; Richards KL; Walko CM; Knepper TC; Soper JT; Weiss J; Grilley-Olson JE; Kim WY; Earp HS; Levine RL; Papaemmanuil E; Zehir A; Hayes DN; Padron E
Clin Cancer Res; 2018 Dec; 24(23):5918-5924. PubMed ID: 29866652
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
[TBL] [Abstract][Full Text] [Related]
14. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.
Jaiswal S; Natarajan P; Silver AJ; Gibson CJ; Bick AG; Shvartz E; McConkey M; Gupta N; Gabriel S; Ardissino D; Baber U; Mehran R; Fuster V; Danesh J; Frossard P; Saleheen D; Melander O; Sukhova GK; Neuberg D; Libby P; Kathiresan S; Ebert BL
N Engl J Med; 2017 Jul; 377(2):111-121. PubMed ID: 28636844
[TBL] [Abstract][Full Text] [Related]
15. Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk.
Tobias DK; Manning AK; Wessel J; Raghavan S; Westerman KE; Bick AG; Dicorpo D; Whitsel EA; Collins J; Correa A; Cupples LA; Dupuis J; Goodarzi MO; Guo X; Howard B; Lange LA; Liu S; Raffield LM; Reiner AP; Rich SS; Taylor KD; Tinker L; Wilson JG; Wu P; Carson AP; Vasan RS; Fornage M; Psaty BM; Kooperberg C; Rotter JI; Meigs J; Manson JE;
Diabetes Care; 2023 Nov; 46(11):1978-1985. PubMed ID: 37756531
[TBL] [Abstract][Full Text] [Related]
16. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
Naqvi K; Garcia-Manero G; Sardesai S; Oh J; Vigil CE; Pierce S; Lei X; Shan J; Kantarjian HM; Suarez-Almazor ME
J Clin Oncol; 2011 Jun; 29(16):2240-6. PubMed ID: 21537048
[TBL] [Abstract][Full Text] [Related]
17. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
Takahashi K; Wang F; Kantarjian H; Doss D; Khanna K; Thompson E; Zhao L; Patel K; Neelapu S; Gumbs C; Bueso-Ramos C; DiNardo CD; Colla S; Ravandi F; Zhang J; Huang X; Wu X; Samaniego F; Garcia-Manero G; Futreal PA
Lancet Oncol; 2017 Jan; 18(1):100-111. PubMed ID: 27923552
[TBL] [Abstract][Full Text] [Related]
18. Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women.
Wiedmeier JE; Kato C; Zhang Z; Lee H; Dunlap J; Nutt E; Rattray R; McKay S; Eide C; Press R; Mori M; Druker B; Dao KH
Exp Hematol; 2016 Sep; 44(9):857-865.e5. PubMed ID: 27235757
[TBL] [Abstract][Full Text] [Related]
19. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
